Replies to post #194928 on Cytodyn Inc (CYDY)

[justdafactss]

Cytodyn shareholders should be realistic that no significant BP is going to look at OTC penny stocks for drugs

And Hygro is correct. Heres the Merck Novamind deal---

Merck & Co. (NYSE:MRK) recently announced their partnership with Novamind to make it a key research site for a clinical trial that will focus on treatment-resistant depression using MDMA and ketamine. The Phase 2 trial will research a compound developed by Merck called MK-1942 to test the currently undescribed molecule for efficacy and safety, with the goal of using it alongside antidepressants for the treatment of treatment-resistant depression.
https://www.financialnewsmedia.com/psychedelics-move-to-the-forefront-of-innovative-research-as-the-fda-approves-large-scale-testing/

LAUGHING

[3X Charm]

Is NVMDF and their CEO under SEC and DOJ investigations Like Nader & CYDY ?

Did they get an RTF on any submissions?

Did their CEO PURPOSELY submit an incomplete BLA?

[HyGro]

Np has repeatedly said they had many interested BPs. But let's get real, he signed up Vyera, the worst biopharma company in the U.S. and got a whopping $5 million. Then there was American Regent -- a generic company that paid NOTHING. Then the three exU.S. partners that have paid nothing for their partnership. None of them are considered BP, just small local drug companies.

I've worked with BP BizDev folks and they are very risk adverse (don't want to lose their job making a mistake) and an OTC penny stock especially one with SEC and DOJ investigations in process. They are investigating because the company misrepresented and manipulated their clinical trial data. A twice convicted CEO, no medical experience, vulture funding, insolvent, etc. Just look at the latest -- Dr. Kelly's "3600% PFS" (that's impossible), Dr. Recknor's "as much as 45%" etc.

There is so much wrong with this company that no self-respecting BP would trust this OTC penny stock pumping management??